Clinical Trial Search

Primary: Concentration of Specific Interferon Gamma (IFN-γ) Antibodies Secreted in Serum Samples — 6279.7 fg/mL

Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants

Primary: Percentage of Participants Without Sore Throat According to TSS Score — 84.35; 73.21; 13.91; 17.86 percentage of participants — p=0.028

Primary: Primary Patency — 94.4 percentage of lesions

Primary: Number of Participants Who Experienced At Least One Adverse Event (AE) — 101 Participants

Primary: Change in Knee Extension Isometric Strength (Peak Torque) Using the Biodex Measurement System — -0.1; 2.2 Nm/kg — p=0.768

Primary: Mean of the Absolute Values of CSRT Difference Month 3 to Month 6 — 25.16; 29.28 micrometers — p=0.1850

Primary: Acetazolamide Arm: Natriuresis 24 h — 324; 300; 211; 190 mmol — p=0.515

Primary: Change From Baseline in Trough Pre-dose FEV1 in Both Arms — 0.036; -0.009 Liters — p=0.028

Primary: Safety and Tolerability of AZD5718 by Assessment of the Number of Participants With Adverse Events Following Oral Administration of SAD (Part A) and MAD (Part B). — 15…

Primary: Incidence of Treatment-emergent Adverse Events (Safety) — 0 adverse events

Primary: Adherence — 4.5; 5.0 hours/night

Primary: Number of Durable Overall CSBM Responders , Mean Replacement Approach — 46; 95; 86 Participants

Primary: Hepatic Glucose Production (Co-primary Outcome) — 2.0; 2.0; 2.1; 1.8 mg/kg-minute

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants